<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373619</url>
  </required_header>
  <id_info>
    <org_study_id>HFNEF-IVA-DIAL</org_study_id>
    <nct_id>NCT01373619</nct_id>
  </id_info>
  <brief_title>Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine</brief_title>
  <official_title>Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with normal ejection fraction is often under diagnosed and certainly under
      treated in hemodialyzed patients. Because of the benefit of reducing heart rate, ivabradine,
      a pure heart-rate lowering agent without effects on blood pressure, is of potential
      therapeutic utility.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiofic changes of diastolic left ventricular function</measure>
    <time_frame>baseline, 1, 3, 6, 9, 12 months</time_frame>
    <description>Measures of diastolic left ventricular function (E and A velocity and deceleration time of mitral inflow and Doppler-Tissue-Imaging E velocity and their ratio) were assessed at baseline and at each scheduled time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in NYHA class</measure>
    <time_frame>baseline, 1,3,6,9,12 months</time_frame>
    <description>Measures of New York Heart Association functional class stratified I to IV at baseline and at each scheduled time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in 6-minutes walking test</measure>
    <time_frame>baseline, 1,3,6,9,12 months</time_frame>
    <description>American Thoracic Society At baseline and at each scheduled time a 6-minutes walking test were performed according ATS Statement. The following measures were analysed at starting and ending test: heart rate; blood pressure, dyspnea according the Borg scale, fatigue according the Borg scale, Spo2%;distance walked, symptoms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>IVABRADINE, HEART FAILURE WITH NORMAL EF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>ivabradine titrated to 7.5 mg BID</description>
    <arm_group_label>IVABRADINE, HEART FAILURE WITH NORMAL EF</arm_group_label>
    <other_name>Procoralan</other_name>
    <other_name>Corlentor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hemodialyzed patients

          -  signs and symptoms of heart failure with normal ejection fraction

          -  sinus rhythm

        Exclusion Criteria:

          -  atrial fibrillation/atrial flutter

          -  valvular heart disease

          -  unstable angina

          -  hospitalization for heart failure prior 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gennaro Cice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chair of Cardiology Second Univesity of Naples</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <name_title>Gennaro Cice, MD Second University of Naples</name_title>
    <organization>Second University of Naples</organization>
  </responsible_party>
  <keyword>Heart failure with normal ejection fraction</keyword>
  <keyword>hemodialysis patients</keyword>
  <keyword>ivabradine</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>NYHA class</keyword>
  <keyword>6-minutes walking test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

